questionsmedicales.fr
Composés polycycliques
Hydrocarbures aromatiques polycycliques
Benzocycloheptènes
Benzocycloheptènes : Questions médicales fréquentes
Termes MeSH sélectionnés :
Connective Tissue Growth Factor
Diagnostic
5
Spectroscopie
Chromatographie
Tests de toxicité
Efficacité
Analyse sanguine
Échantillons biologiques
Marqueurs biologiques
Exposition
Imagerie moléculaire
Distribution tissulaire
Symptômes
5
Effets secondaires
Réactions allergiques
Symptômes neurologiques
Troubles de la coordination
Éruptions cutanées
Réaction allergique
Système respiratoire
Irritations
Prévention
5
Équipements de protection
Protocoles de sécurité
Milieu industriel
Exposition
Réglementations
Usage industriel
Évaluation des risques
Environnements de travail
Traitements
5
Intoxication
Soins symptomatiques
Antidotes
Composés chimiques
Antihistaminiques
Réactions allergiques
Hospitalisation
Symptômes graves
Suivi médical
Effets à long terme
Complications
5
Complications
Lésions organiques
Cancers
Potentiel cancérigène
Effets sur la reproduction
Études animales
Allergies
Sensibilisations
Système immunitaire
Infections
Facteurs de risque
5
Travailleurs
Industrie chimique
Prédispositions génétiques
Sensibilité aux toxines
Antécédents médicaux
Allergies
Environnement de travail
Ventilation
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Benzocycloheptènes : Questions médicales les plus fréquentes",
"headline": "Benzocycloheptènes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Benzocycloheptènes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-11",
"dateModified": "2025-03-08",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Benzocycloheptènes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Hydrocarbures aromatiques polycycliques",
"url": "https://questionsmedicales.fr/mesh/D011084",
"about": {
"@type": "MedicalCondition",
"name": "Hydrocarbures aromatiques polycycliques",
"code": {
"@type": "MedicalCode",
"code": "D011084",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Dibenzocycloheptènes",
"alternateName": "Dibenzocycloheptenes",
"url": "https://questionsmedicales.fr/mesh/D003986",
"about": {
"@type": "MedicalCondition",
"name": "Dibenzocycloheptènes",
"code": {
"@type": "MedicalCode",
"code": "D003986",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Amitriptyline",
"alternateName": "Amitriptyline",
"url": "https://questionsmedicales.fr/mesh/D000639",
"about": {
"@type": "MedicalCondition",
"name": "Amitriptyline",
"code": {
"@type": "MedicalCode",
"code": "D000639",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Butaclamol",
"alternateName": "Butaclamol",
"url": "https://questionsmedicales.fr/mesh/D002069",
"about": {
"@type": "MedicalCondition",
"name": "Butaclamol",
"code": {
"@type": "MedicalCode",
"code": "D002069",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.230"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Cyproheptadine",
"alternateName": "Cyproheptadine",
"url": "https://questionsmedicales.fr/mesh/D003533",
"about": {
"@type": "MedicalCondition",
"name": "Cyproheptadine",
"code": {
"@type": "MedicalCode",
"code": "D003533",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Loratadine",
"alternateName": "Loratadine",
"url": "https://questionsmedicales.fr/mesh/D017336",
"about": {
"@type": "MedicalCondition",
"name": "Loratadine",
"code": {
"@type": "MedicalCode",
"code": "D017336",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Loratadine",
"alternateName": "Loratadine",
"url": "https://questionsmedicales.fr/mesh/D017336",
"about": {
"@type": "MedicalCondition",
"name": "Loratadine",
"code": {
"@type": "MedicalCode",
"code": "D017336",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.340.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Maléate de dizocilpine",
"alternateName": "Dizocilpine Maleate",
"url": "https://questionsmedicales.fr/mesh/D016291",
"about": {
"@type": "MedicalCondition",
"name": "Maléate de dizocilpine",
"code": {
"@type": "MedicalCode",
"code": "D016291",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.380"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nortriptyline",
"alternateName": "Nortriptyline",
"url": "https://questionsmedicales.fr/mesh/D009661",
"about": {
"@type": "MedicalCondition",
"name": "Nortriptyline",
"code": {
"@type": "MedicalCode",
"code": "D009661",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.535"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protriptyline",
"alternateName": "Protriptyline",
"url": "https://questionsmedicales.fr/mesh/D011530",
"about": {
"@type": "MedicalCondition",
"name": "Protriptyline",
"code": {
"@type": "MedicalCode",
"code": "D011530",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.615.181.384.650"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Benzocycloheptènes",
"alternateName": "Benzocycloheptenes",
"code": {
"@type": "MedicalCode",
"code": "D001567",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jiatian Li",
"url": "https://questionsmedicales.fr/author/Jiatian%20Li",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Xiangwen Tan",
"url": "https://questionsmedicales.fr/author/Xiangwen%20Tan",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Huanfeng Jiang",
"url": "https://questionsmedicales.fr/author/Huanfeng%20Jiang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
},
{
"@type": "Person",
"name": "Wanqing Wu",
"url": "https://questionsmedicales.fr/author/Wanqing%20Wu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Connective Tissue Growth Factor in Idiopathic Pulmonary Fibrosis: Breaking the Bridge.",
"datePublished": "2022-05-28",
"url": "https://questionsmedicales.fr/article/35682743",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms23116064"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mechanosensitive expression of the mesenchymal subtype marker connective tissue growth factor in glioblastoma.",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36056123",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-022-19175-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "The context-dependent role of transforming growth factor-β/miR-378a-3p/connective tissue growth factor in vascular calcification: a translational study.",
"datePublished": "2023-02-13",
"url": "https://questionsmedicales.fr/article/36787443",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18632/aging.204518"
}
},
{
"@type": "ScholarlyArticle",
"name": "MiR-18a-5p Targets Connective Tissue Growth Factor Expression and Inhibits Transforming Growth Factor β2-Induced Trabecular Meshwork Cell Contractility.",
"datePublished": "2022-08-22",
"url": "https://questionsmedicales.fr/article/36011411",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/genes13081500"
}
},
{
"@type": "ScholarlyArticle",
"name": "Connective tissue growth factor promotes cementogenesis and cementum repair via Cx43/β-catenin axis.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/36068594",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13287-022-03149-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Hydrocarbures aromatiques polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011084"
},
{
"@type": "ListItem",
"position": 4,
"name": "Benzocycloheptènes",
"item": "https://questionsmedicales.fr/mesh/D001567"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Benzocycloheptènes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Benzocycloheptènes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Benzocycloheptènes",
"description": "Comment identifier les benzocycloheptènes ?\nQuels tests sont utilisés pour les benzocycloheptènes ?\nLes benzocycloheptènes sont-ils détectables dans le sang ?\nY a-t-il des marqueurs spécifiques pour ces composés ?\nPeut-on utiliser l'imagerie pour les benzocycloheptènes ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Connective+Tissue+Growth+Factor#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Benzocycloheptènes",
"description": "Quels sont les effets secondaires des benzocycloheptènes ?\nLes benzocycloheptènes causent-ils des douleurs ?\nY a-t-il des symptômes neurologiques associés ?\nPeut-on observer des symptômes cutanés ?\nLes benzocycloheptènes affectent-ils le système respiratoire ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Connective+Tissue+Growth+Factor#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Benzocycloheptènes",
"description": "Comment prévenir l'exposition aux benzocycloheptènes ?\nY a-t-il des formations pour manipuler ces composés ?\nQuels sont les risques en milieu industriel ?\nDes réglementations existent-elles pour leur usage ?\nComment évaluer les risques d'exposition ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Connective+Tissue+Growth+Factor#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Benzocycloheptènes",
"description": "Comment traiter une intoxication aux benzocycloheptènes ?\nY a-t-il des antidotes pour ces composés ?\nQuels médicaments peuvent aider en cas d'allergie ?\nLes benzocycloheptènes nécessitent-ils une hospitalisation ?\nComment gérer les effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Connective+Tissue+Growth+Factor#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Benzocycloheptènes",
"description": "Quelles complications peuvent survenir avec ces composés ?\nLes benzocycloheptènes peuvent-ils causer des cancers ?\nY a-t-il des effets sur la reproduction ?\nPeut-on développer des allergies à long terme ?\nLes benzocycloheptènes affectent-ils le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Connective+Tissue+Growth+Factor#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Benzocycloheptènes",
"description": "Qui est le plus à risque d'exposition ?\nL'âge influence-t-il la sensibilité ?\nY a-t-il des prédispositions génétiques ?\nLes antécédents médicaux jouent-ils un rôle ?\nL'environnement de travail influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D001567?mesh_terms=Connective+Tissue+Growth+Factor#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier les benzocycloheptènes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques de spectroscopie et de chromatographie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les benzocycloheptènes ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de toxicité et d'efficacité sont réalisés en laboratoire."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes sont-ils détectables dans le sang ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être détectés par des analyses spécifiques dans des échantillons biologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour ces composés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs biologiques peuvent indiquer l'exposition à ces composés."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour les benzocycloheptènes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie moléculaire peut aider à visualiser leur distribution dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des benzocycloheptènes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent provoquer des nausées, des vertiges ou des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes causent-ils des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs peuvent survenir en cas de toxicité ou d'allergie."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des maux de tête ou des troubles de la coordination peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent survenir en cas de réaction allergique."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes affectent-ils le système respiratoire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition excessive peut entraîner des irritations respiratoires."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition aux benzocycloheptènes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection et suivre les protocoles de sécurité en laboratoire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des formations pour manipuler ces composés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des formations spécifiques sont souvent requises pour les chercheurs."
}
},
{
"@type": "Question",
"name": "Quels sont les risques en milieu industriel ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs peuvent être exposés à des niveaux élevés sans protection adéquate."
}
},
{
"@type": "Question",
"name": "Des réglementations existent-elles pour leur usage ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des réglementations strictes encadrent leur utilisation en laboratoire et en industrie."
}
},
{
"@type": "Question",
"name": "Comment évaluer les risques d'exposition ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des évaluations de risque doivent être effectuées régulièrement dans les environnements de travail."
}
},
{
"@type": "Question",
"name": "Comment traiter une intoxication aux benzocycloheptènes ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'élimination de l'exposition et des soins symptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des antidotes pour ces composés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas d'antidote spécifique pour les benzocycloheptènes."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent aider en cas d'allergie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antihistaminiques peuvent être utilisés pour traiter les réactions allergiques."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes nécessitent-ils une hospitalisation ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hospitalisation peut être nécessaire en cas de symptômes graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets à long terme ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi médical régulier est recommandé pour surveiller les effets à long terme."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces composés ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions organiques peuvent survenir en cas d'exposition prolongée."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes peuvent-ils causer des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent un potentiel cancérigène, mais des recherches supplémentaires sont nécessaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets sur la reproduction ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets néfastes sur la reproduction ont été observés dans certaines études animales."
}
},
{
"@type": "Question",
"name": "Peut-on développer des allergies à long terme ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des sensibilisations peuvent se développer avec une exposition répétée."
}
},
{
"@type": "Question",
"name": "Les benzocycloheptènes affectent-ils le système immunitaire ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une exposition prolongée peut altérer la fonction immunitaire, augmentant les infections."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'exposition ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs en laboratoire et en industrie chimique sont les plus exposés."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la sensibilité ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes et les personnes âgées peuvent être plus sensibles aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions génétiques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines prédispositions génétiques peuvent augmenter la sensibilité aux toxines."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'allergies ou de maladies respiratoires augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'environnement de travail influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un environnement de travail mal ventilé augmente le risque d'exposition."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 08/03/2025
Contenu vérifié selon les dernières recommandations médicales
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Luminescent Materials and Devices, School of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510641, P.R. China.
Publications dans "Benzocycloheptènes" :
CTGF is upregulated in patients with idiopathic pulmonary fibrosis (IPF), characterized by the deposition of a pathological extracellular matrix (ECM). Additionally, many omics studies confirmed that ...
Mechanical forces created by the extracellular environment regulate biochemical signals that modulate the inter-related cellular phenotypes of morphology, proliferation, and migration. A stiff microen...
Vascular calcification (VC) constitutes an important vascular pathology with prognostic importance. The pathogenic role of transforming growth factor-β (TGF-β) in VC remains unclear, with heterogeneou...
Two approaches, exogenous administration and endogenous expression upon osteogenic media (OM) exposure, were adopted. Aortic smooth muscle cells (ASMCs) were subjected to TGF-β1 alone, OM alone, or bo...
TGF-β1 treatment induced a significant dose-responsive increase in ASMC calcification without or with OM at the mature but not early or mid-term VC period. On the other hand, OM alone induced VC accom...
We showed that TGF-β1 played a context-dependent role in VC, involving a time-dependent self-regulatory loop of TGF-β1/miR-378a-3p/CTGF signaling. Our findings may assist subsequent studies in devisin...
Increased trabecular meshwork (TM) cell and tissue contractility is a driver of the reduced outflow facility and elevation of intraocular pressure (IOP) associated with primary open-angle glaucoma (PO...
Orthodontic tooth movement inevitably induces cementum resorption, which is an urgent problem for orthodontists to confront. Human periodontal ligament stem cells (hPDLSCs) exert an important role in ...
A cementum defect model was established by tooth movement with heavy forces, and the cementum repair effect of CTGF was observed via micro-CT, HE staining and immunohistochemical staining. RT‒qPCR, we...
Local oral administration of CTGF to the cementum defects in vivo facilitated cementum repair. CTGF facilitated the cementogenesis of hPDLSCs in a concentration-dependent manner. Cx43 acted as a downs...
Taken together, these data demonstrate that CTGF promotes cementum repair and cementogenesis through activation of the Cx43/β-catenin signalling axis....
Coronavirus disease-2019 (COVID-19) results in acute lung injury. This study examined the usefulness of serum transforming growth factor-beta 1 (TGF-β1) and connective tissue growth factor (CTGF) leve...
Fifty patients with confirmed COVID-19 and pulmonary involvement between September 2020, and February 2021 (Group 1) and 45 healthy controls (Group 2) were classified into three subgroups based on cli...
Significantly higher mean serum TGF-β1 and CTGF levels were observed on both days in Group 1 than in the control group. The mean serum TGF-β1 and CTGF levels on day 7 were also significantly higher th...
TGF-β1 and CTGF are potential markers that can distinguish COVID-19 patients with pulmonary involvement and indicate disease severity. These findings may be useful for initiating treatment for early-s...
Connective tissue growth factor (CTGF) has diagnostic value for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD) in children; however, its value in adult patients r...
CTGF is a biomarker of PAH associated with CHD. It can be used for early diagnosis and severity assessment in adult patients with CHD-PAH....
This study aims to investigate the role of shear wave elastography (SWE) and connective tissue growth factor (CTGF) in the assessment of papillary thyroid carcinoma (PTC) prognosis....
CTGF expression was detected with immunohistochemistry. Clinical and pathological data were collected. Parameters of conventional ultrasound combined with SWE were also collected. The relationship amo...
Univariate analysis showed that patients with high risk of PTC were characterized with male, Uygur ethnicity, increased expression of CTGF, convex lesions, calcified, incomplete capsule, intranodular ...
SWE and CTGF are of great value in the risk assessment of PTC. The degree of fibrosis of PTC is closely related to the prognosis. The hardness of PTC lesions and the expression level of CTGF are corre...
Triple-negative breast cancer (TNBC) is characterized by aggressive behavior and limited treatment options, necessitating the identification of novel therapeutic targets. In this study, we investigate...
Reduction of histone deacetylase (HDAC) 2 expression and activity may contribute to amplified inflammation in patients with severe asthma. Connective tissue growth factor (CTGF) is a key mediator of a...
The role of the HDAC2/Sin3A/MeCP2 corepressor complex in endothelin (ET)-1-stimulated CTGF production in human lung fibroblasts (WI-38) was investigated. We also evaluated the expression of HDAC2, Sin...
HDAC2 suppressed ET-1-induced CTGF expression in WI-38 cells. ET-1 treatment reduced HDAC2 activity and increased H3 acetylation in a time-dependent manner. Furthermore, overexpression of HDAC2 inhibi...
The HDAC2/Sin3A/MeCP2 corepressor complex is an endogenous inhibitor of CTGF in lung fibroblasts. Additionally, HDAC2 and Sin3A may be of greater importance than MeCP2 in the pathogenesis of airway fi...